v3.26.3
Segment Information - Schedule of the Reportable Segment and Includes the Reconciliation to Consolidated Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]                
Revenue $ 259,691     $ 170,992     $ 669,269 $ 442,497
Cost of revenue (excluding amortization and depreciation) 17,804     11,912     46,093 35,149
Other research and development 3,258     4,744 [1]     20,316 11,942 [1]
General and administrative expense (excluding share-based compensation expense) 17,660     19,739     64,299 44,623
Selling and marketing expense (excluding stock-based compensation expense) 166,701     114,200     477,251 305,864
Stock-based compensation expense 26,356     23,103     76,942 71,022
Loss (Gain) in fair value of contingent consideration (2,380)     13,185     (3,286) 6,595
Interest expense, net 1,721     1,120 [2]     4,446 5,385 [2]
Other segment items 1,695     1,607 [3]     4,984 14,193 [3]
Segment net loss (12,877)     (47,229)     (128,733) (154,615)
Reconciliation of net loss                
Adjustments and reconciling items 0     0     0 0
Net loss (12,877) $ (51,314) $ (64,542) (47,229) $ (47,973) $ (59,413) (128,733) (154,615)
Solriamfetol                
Segment Reporting [Line Items]                
Research and development expense (reversal) recognized 16,471     9,518     41,099 32,094
AXS-05                
Segment Reporting [Line Items]                
Research and development expense (reversal) recognized 12,974     13,855     35,369 42,896
AXS-07                
Segment Reporting [Line Items]                
Research and development expense (reversal) recognized 4,793     4,825     14,847 15,379
AXS-12                
Segment Reporting [Line Items]                
Research and development expense (reversal) recognized 2,013     1,873     5,900 6,019
AXS-14                
Segment Reporting [Line Items]                
Research and development expense (reversal) recognized $ 3,502     $ (1,460)     $ 9,742 $ 5,951
[1] Other research and development expenses primarily consist of facilities charges, third party consultant costs, costs related to other product candidates, costs related to asset acquisitions, and other unallocated costs.
[2] Interest expense, net of $1,721 for the three months ended September 30, 2026 comprises (i) consolidated interest expense of $3,415 and (ii) consolidated interest income of $1,694. Interest expense, net of $4,446 for the nine months ended September 30, 2026 comprises (i) consolidated interest expense of $9,707 and (ii) consolidated interest income of $5,261. Interest expense, net of $1,120 for the three months ended September 30, 2025 comprises (i) consolidated interest expense of $3,375 and (ii) consolidated interest income of $2,255. Interest expense, net of $5,385 for the nine months ended September 30, 2025 comprises (i) consolidated interest expense of $12,719 and (ii) consolidated interest income of $7,334.
[3] Other segment items included in Segment net loss include intangible asset amortization, loss on debt extinguishment, and other miscellaneous items.